Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells - PubMed (original) (raw)
. 2006 Jul 15;108(2):645-52.
doi: 10.1182/blood-2005-11-4639. Epub 2006 Mar 14.
Michael Pranpat, Purva Bali, Maria Balasis, Sandhya Kumaraswamy, Sandhya Boyapalle, Kathy Rocha, Jie Wu, Francis Giles, Paul W Manley, Peter Atadja, Kapil Bhalla
Affiliations
- PMID: 16537804
- DOI: 10.1182/blood-2005-11-4639
Free article
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Warren Fiskus et al. Blood. 2006.
Free article
Abstract
AMN107 (Novartis Pharmaceuticals, Basel, Switzerland) has potent in vitro and in vivo activity against the unmutated and most common mutant forms of Bcr-Abl. Treatment with the histone deacetylase inhibitor LBH589 (Novartis) depletes Bcr-Abl levels. We determined the effects of AMN107 and/or LBH589 in Bcr-Abl-expressing human K562 and LAMA-84 cells, as well as in primary chronic myelogenous leukemia (CML) cells. AMN107 was more potent than imatinib mesylate (IM) in inhibiting Bcr-Abl tyrosine kinase (TK) activity and attenuating p-STAT5, p-AKT, Bcl-x(L), and c-Myc levels in K562 and LAMA-84 cells. Cotreatment with LBH589 and AMN107 exerted synergistic apoptotic effects with more attenuation of p-STAT5, p-ERK1/2, c-Myc, and Bcl-x(L) and increases in p27 and Bim levels. LBH589 attenuated Bcr-Abl levels and induced apoptosis of mouse pro-B BaF3 cells containing ectopic expression of Bcr-Abl or the IM-resistant, point-mutant Bcr-AblT315I and Bcr-AblE255K. Treatment with LBH589 also depleted Bcr-Abl levels and induced apoptosis of IM-resistant primary human CML cells, including those with expression of Bcr-AblT315I. As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of cell viability of primary IM-resistant CML cells. Thus, cotreatment with LBH589 and AMN107 is active against cultured or primary IM-resistant CML cells, including those with expression of Bcr-AblT315I.
Similar articles
- Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K. Fiskus W, et al. Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980. Clin Cancer Res. 2006. PMID: 17020995 - Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. George P, et al. Blood. 2005 Feb 15;105(4):1768-76. doi: 10.1182/blood-2004-09-3413. Epub 2004 Oct 28. Blood. 2005. PMID: 15514006 - Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Nimmanapalli R, et al. Blood. 2003 Apr 15;101(8):3236-9. doi: 10.1182/blood-2002-08-2675. Epub 2002 Nov 21. Blood. 2003. PMID: 12446442 - The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T, Ashihara E, Kimura S. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review. - AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. Weisberg E, et al. Br J Cancer. 2006 Jun 19;94(12):1765-9. doi: 10.1038/sj.bjc.6603170. Epub 2006 May 23. Br J Cancer. 2006. PMID: 16721371 Free PMC article. Review.
Cited by
- Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T. Matsuda Y, et al. Cancer Sci. 2016 Jul;107(7):1029-38. doi: 10.1111/cas.12965. Epub 2016 Jun 21. Cancer Sci. 2016. PMID: 27166836 Free PMC article. - Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN. Wang Y, et al. Blood. 2009 Dec 3;114(24):5024-33. doi: 10.1182/blood-2009-05-222133. Epub 2009 Oct 14. Blood. 2009. PMID: 19828702 Free PMC article. - Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Bluethner T, et al. World J Gastroenterol. 2007 Sep 21;13(35):4761-70. doi: 10.3748/wjg.v13.i35.4761. World J Gastroenterol. 2007. PMID: 17729398 Free PMC article. - Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.
Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Rubbi L, et al. Sci Signal. 2011 Mar 29;4(166):ra18. doi: 10.1126/scisignal.2001314. Sci Signal. 2011. PMID: 21447799 Free PMC article. - Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation.
Liu L, Sun X, Xie Y, Zhuang Y, Yao R, Xu K. Liu L, et al. Molecules. 2018 Apr 30;23(5):1044. doi: 10.3390/molecules23051044. Molecules. 2018. PMID: 29710846 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous